Treatment of acne with cyproterone acetate and ethinyl estradiol.
Tablets containing 2 mg cyproterone acetate and 0.05 mg ethinyl estradiol in a calendar package of 21 days were used as an oral contraceptive to treat acne. The series comprised 20 patients. The women were 18--43 years of age, and all had acne which had previously been resistant to therapy. The treatment was continued for 6 months. Serum testosterone, 17-OHCS, 17-KS, serum ALAT and gamma-GT were recorded prior to the treatment at 3 and 6 months. Ten patients responded well to the treatment, 5 responded moderately well, 3 experienced no change, and 2 became worse. The serum testosterone level fell during the therapy and the ALAT level rose, though only one pathological ALAT value was recorded.
D015065:17-Hydroxycorticosteroids / Q000097:blood; D015068:17-Ketosteroids / Q000097:blood; D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003534:Cyproterone / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D013607:Tablets; D013739:Testosterone / Q000097:blood
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D004338:Drug Combinations; D013607:Tablets; D013739:Testosterone; D004997:Ethinyl Estradiol; D003534:Cyproterone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase